ProSTAR: A Phase 1b/2 Study of CPI-1205 a Small Molecule Inhibitor of EZH2 Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer
Brief description of study
This Phase 1b/2 trial is testing a drug, CPI-1205, that targets the EPIGENETICS of metastatic Castration Resistant Prostate Cancer. The main goal of the study is to find out if CPI-1205 can be an effective anti-cancer treatment for men with metastatic castration resistant prostate cancer (CRPC). CPI-1205 will be administered alone or with cobicistat, combined with enzalutamide or abiraterone/prednisone.
Clinical Study Identifier: s18-00024
ClinicalTrials.gov Identifier: NCTs18-00024
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
